Analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to post earnings per share of ($0.12) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for ZIOPHARM Oncology’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.14). ZIOPHARM Oncology reported earnings of ($0.13) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 7.7%. The firm is scheduled to issue its next earnings report after the market closes on Wednesday, August 8th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.45). For the next year, analysts anticipate that the company will post earnings of ($0.41) per share, with EPS estimates ranging from ($0.53) to ($0.22). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Thursday, May 10th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.15 million for the quarter, compared to the consensus estimate of $1.55 million.
Several equities analysts recently weighed in on the stock. Zacks Investment Research cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, May 9th. ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. JPMorgan Chase & Co. lowered shares of ZIOPHARM Oncology from a “neutral” rating to an “underweight” rating in a research report on Monday, June 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.50 price objective on shares of ZIOPHARM Oncology in a research report on Monday, May 14th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. ZIOPHARM Oncology has a consensus rating of “Hold” and an average price target of $5.25.
ZIOPHARM Oncology traded down $0.13, hitting $2.33, during trading on Tuesday, according to MarketBeat. 1,093,321 shares of the company traded hands, compared to its average volume of 1,072,271. The stock has a market capitalization of $350.92 million, a price-to-earnings ratio of -4.40 and a beta of 1.33. ZIOPHARM Oncology has a 1 year low of $2.32 and a 1 year high of $6.67.
Hedge funds have recently added to or reduced their stakes in the business. Chessman Wealth Strategies RIA bought a new stake in shares of ZIOPHARM Oncology in the 2nd quarter worth about $218,000. Summit Trail Advisors LLC increased its position in ZIOPHARM Oncology by 351.7% during the 1st quarter. Summit Trail Advisors LLC now owns 125,392 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 97,632 shares during the period. UBS Group AG increased its position in ZIOPHARM Oncology by 35.3% during the 1st quarter. UBS Group AG now owns 872,376 shares of the biotechnology company’s stock valued at $3,420,000 after purchasing an additional 227,812 shares during the period. Wealthcare Advisory Partners LLC purchased a new position in ZIOPHARM Oncology during the 1st quarter valued at about $314,000. Finally, Russell Investments Group Ltd. purchased a new position in ZIOPHARM Oncology during the 1st quarter valued at about $911,000. Institutional investors and hedge funds own 39.92% of the company’s stock.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
See Also: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.